Clues to quality of journals
Open Access Policy of Helmholtz Association 2016
CC Licencences
Publication Metrics
Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Statistics (last 5 years)
OA Publications
Submit Publication
Import publication from...
Report missing publication
Contact persons
Help
Text
Endnote (RIS)
BibTeX
Publ. Version/Full Text
DOI
PMC
 |
Open Access Gold |
|
as soon as is submitted to ZB.
Unveiling therapeutic targets for esophageal cancer: A comprehensive review.
Curr. Oncol. 30, 9542-9568 (2023)
Esophageal cancer is a highly aggressive and deadly disease, ranking as the sixth leading cause of cancer-related deaths worldwide. Despite advances in treatment, the prognosis remains poor. A multidisciplinary approach is crucial for achieving complete remission, with treatment options varying based on disease stage. Surgical intervention and endoscopic treatment are used for localized cancer, while systemic treatments like chemoradiotherapy and targeted drug therapy play a crucial role. Molecular markers such as HER2 and EGFR can be targeted with drugs like trastuzumab and cetuximab, and immunotherapy drugs like pembrolizumab and nivolumab show promise by targeting immune checkpoint proteins. Epigenetic modifications offer new avenues for targeted therapy. Treatment selection depends on factors like stage, tumor location, and patient health, with post-operative and rehabilitation care being essential. Early diagnosis, appropriate treatment, and supportive care are key to improving outcomes. Continued research is needed to develop effective targeted drugs with minimal side effects. This review serves as a valuable resource for clinicians and researchers dedicated to enhancing esophageal cancer treatment outcomes.
Impact Factor
Scopus SNIP
Altmetric
2.600
0.000
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Review
Keywords
Esophageal Cancer ; Molecular Markers ; Multidisciplinary Approach ; Prognosis ; Targeted Therapy; Quality-of-life; Endoscopic Submucosal Dissection; Minimally Invasive Mckeown; Endothelial Growth-factor; Squamous-cell Carcinoma; Term-follow-up; Mucosal Resection; Esophagogastric Junction; Barretts-esophagus; Management
Language
english
Publication Year
2023
HGF-reported in Year
2023
ISSN (print) / ISBN
1198-0052
e-ISSN
1718-7729
Journal
Current Oncology
Quellenangaben
Volume: 30,
Issue: 11,
Pages: 9542-9568
Publisher
MDPI
Publishing Place
St Alban-anlage 66, Ch-4052 Basel, Switzerland
Reviewing status
Peer reviewed
Institute(s)
Institute of Lung Health and Immunity (LHI)
POF-Topic(s)
80000 - German Center for Lung Research
Research field(s)
Lung Research
PSP Element(s)
G-501810-007
WOS ID
001119955200001
PubMed ID
37999111
Erfassungsdatum
2023-12-19